Enovis Corporation
NYSE:ENOVMedical - Devices
+$0.73 today
- Market cap
- $1.56B
- Beta
- 1.49
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$20.02
Volume 0.88M
Average 0.99M
ENOV Common Stock Repurchased
Cash spent buying back the company's own shares.
Enovis CorporationNYSE: ENOV
Common Stock Repurchased · Q1 FY2026 · quarter ended Apr 2026
Common stock repurchased outflow grows to $0
Q1 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.
Context
- Common stock repurchased amounted to 0.0% of revenue in FY2025, down 0.2 pp from a year earlier.
- Common stock repurchased increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Repurchased history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Common Stock Repurchased | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | +100.0% |
| FY2024 | 2024-12-31 | (4.77M) | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Common Stock Repurchased vs competitors
How ENOV compares with its peers on the latest reported figures
- ENOV's LTM Apr 2026 common stock repurchased of $0 is the 13th largest of the 16 companies compared; the peer median is $16M.
- Common stock repurchased amounts to 0.0% of revenue for ENOV, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $939.8M | +145.8% | +39.8% | 26.4% | |
| LTM Jun 2026 | $301.5M | +200.9% | +18.7% | 8.4% | |
| LTM Feb 2026 | $120.11M | +426.8% | -2.9% | 19.2% | |
| LTM Jul 2026 | $111.2M | -66.5% | -7.8% | 2.9% | |
| LTM Jul 2026 | $105M | -80.0% | +28.5% | 2.2% | |
| LTM Sep 2026 | $61.1M | -54.2% | +59.9% | 2.7% | |
| LTM Jul 2026 | $17.9M | +175.4% | +73.6% | 2.0% | |
| LTM Jun 2026 | $16M | -4.8% | -38.7% | 0.6% | |
| LTM Jul 2026 | $4.92M | +24515.0% | — | 0.4% | |
| LTM Jun 2026 | $2.65M | +199.3% | +7.9% | 0.4% | |
| LTM Mar 2026 | $1.54M | +80.4% | +318.7% | 0.6% | |
| LTM Mar 2026 | $200K | -91.7% | -34.6% | 0.1% | |
| LTM Apr 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | +100.0% | -11.5% | 0.0% | |
| Peer median (excluding ENOV) | $16M | +100.0% | +13.3% | 0.6% | |
Competitors are the stored peer set for ENOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 76.28M | (11.76M) | (33.26M) | (824.82M) | (1.18B) |
| Depreciation & Amortization | 262.92M | 219.71M | 217.1M | 284.8M | 294.38M |
| Deferred Income Tax | (22.19M) | 6.32M | (27.41M) | (10.02M) | (2.23M) |
| Stock-Based Compensation | 35.35M | 38.96M | 34.07M | 29.66M | 32.92M |
| Change in Working Capital | (17.1M) | (220.49M) | (27.27M) | (13.93M) | 15.47M |
| Accounts Receivables | (110.99M) | (45.19M) | (16.32M) | (57.05M) | (10.75M) |
| Inventory | (129.97M) | (118.79M) | (24.74M) | 39.07M | (11.98M) |
| Accounts Payables | 178.47M | (11.84M) | (6.64M) | 13.98M | (1.14M) |
| Other Working Capital | 45.38M | (44.67M) | 20.42M | (9.93M) | 39.34M |
| Other Non-Cash Items | 20.84M | (88.59M) | (28.24M) | 647.81M | 1.06B |
| Operating Cash Flow | 356.1M | (55.86M) | 134.99M | 113.5M | 217.29M |
| Capital Expenditures | (104.24M) | (105.45M) | (122.22M) | (180.71M) | (197.38M) |
| Acquisitions (Net) | (223.27M) | (73.68M) | (152.82M) | (769.91M) | 16.4M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 7.03M | 2.75M | 32.57M | (4.85M) | 1.6M |
| Investing Cash Flow | (320.48M) | (176.39M) | (242.47M) | (955.47M) | (179.37M) |
| Debt Repayment | (150.41M) | (1.59B) | 217.2M | 859.23M | (43.6M) |
| Common Stock Issued | 745.18M | 5.81M | 1.78M | 1.87M | 1.32M |
| Common Stock Repurchased | 0 | 0 | 0 | (4.77M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.87M) | 1.12B | (91.17M) | (9.51M) | (10.12M) |
| Financing Cash Flow | 584.91M | (465.13M) | 127.8M | 846.82M | (52.4M) |
| Effect of Forex Changes | (2.23M) | 2.3M | 219K | (1.52M) | 2.7M |
| Net Change in Cash | 618.3M | (695.08M) | 20.54M | 3.34M | (11.78M) |
| Free Cash Flow | 251.86M | (161.31M) | 12.77M | (67.21M) | 19.92M |
Enovis Corporation
NYSE:ENOV
Intrinsic Alpha fair value
Locked
Current Price
$27.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.